ASO Author Reflections: Population-Derived Outcome by Treatment-Intent for LAPC

Patrik Larsson^{1

2}, Oskar Swartling^{3

4}, Diana Cheraghi⁴, Ajnon Khawaja⁴, Kjetil Søreide^{3

4}, Ernesto Sparrelid^{3

4}, Poya Ghorbani^{3

4}

Affiliations

¹ Division of Surgery and Oncology, Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm, Sweden. patrik.larsson@ki.se.
² Karolinska University Hospital, Huddinge, Sweden. patrik.larsson@ki.se.
³ Division of Surgery and Oncology, Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm, Sweden.
⁴ Karolinska University Hospital, Huddinge, Sweden.

Patrik Larsson et al. Ann Surg Oncol. 2025 Jan.

. 2025 Jan;32(1):533-534.

doi: 10.1245/s10434-024-16380-9. Epub 2024 Oct 25.

Patrik Larsson^{1

2}, Oskar Swartling^{3

4}, Diana Cheraghi⁴, Ajnon Khawaja⁴, Kjetil Søreide^{3

4}, Ernesto Sparrelid^{3

4}, Poya Ghorbani^{3

4}

¹ Division of Surgery and Oncology, Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm, Sweden. patrik.larsson@ki.se.
² Karolinska University Hospital, Huddinge, Sweden. patrik.larsson@ki.se.
³ Division of Surgery and Oncology, Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm, Sweden.
⁴ Karolinska University Hospital, Huddinge, Sweden.

No abstract available

References

1. Farnes I, Kleive D, Verbeke CS, Aabakken L, Issa-Epe A, Smastuen MC, et al. Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data from a population-based, prospective cohort study (NORPACT-2). BJS Open. 2023;7(6). - PMC - PubMed
1. Rangelova E, Wefer A, Persson S, Valente R, Tanaka K, Orsini N, et al. Surgery improves survival after neoadjuvant therapy for borderline and locally advanced pancreatic cancer: a single institution experience. Ann Surg. 2021;273(3):579–86. - PubMed
1. Stoop TF, Seelen LWF, van’t Land FR, Lutchman KRD, van Dieren S, Lips DJ, et al. Nationwide use and outcome of surgery for locally advanced pancreatic cancer following induction chemotherapy. Ann Surg Oncol. 2024;31(4):2640–53. - PubMed
1. Hackert T, Sachsenmaier M, Hinz U, Schneider L, Michalski CW, Springfeld C, et al. Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients. Ann Surg. 2016;264(3):457–63. - PubMed
1. Larsson P, Swartling O, Cheraghi D, et al. Assessment of outcomes by intention-to-treat comparison for locally advanced pancreatic cancer: a population-derived cohort study. Ann Surg Oncol. 2024. 10.1245/s10434-024-16291-9. - PMC - PubMed